(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 26 April 2001 (26.04.2001)

PCT

(10) International Publication Number WO 01/28360 A1

(51) International Patent Classification⁷: 1/29, 1/30

A23L 1/09,

(74) Agent: BROWNE, Robin, Forsythe; Urquhart-Dykes & Lord, Tower House, Merrion Way, Leeds LS2 8PA (GB).

- (21) International Application Number: PCT/GB00/03995
- (22) International Filing Date: 18 October 2000 (18.10.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

9924650.6

19 October 1999 (19.10.1999) GB

- (71) Applicant (for all designated States except US): MARATHADE LIMITED [GB/GB]; 175 Woodhouse Lane, Leeds LS2 3AR (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KING, Roderick, Fredrick, Gerardus, Joseph [GB/GB]; 73 St Davids Road, Otley, West Yorkshire LS21 2RG (GB). GALE, Richard, William [GB/GB]; 31 Middlecave Road, Malton, North Yorkshire YO17 7NE (GB). LESTER, Simon, Edmund, George [GB/GB]; 24E Thorney Crescent, Morgan's Walk, London SW11 3TT (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ENERGY FOOD PRODUCT

ENERGY FOOD PRODUCT

This invention relates to high energy multi-saccharide food products containing the substance galactose, which find use as an ergogenic aid, particularly but not exclusively for persons participating in sports or other forms of exercise. The products of this invention also find use in cases of hunger or fatigue in the general population.

Exercise makes excessive demands on substrates both within and external to the muscle. Carbohydrates are especially important as precursors of glycogen both in liver and muscle and as an energy source which can be used immediately. Accordingly there is a need for a short term energy supply during anaerobic and aerobic conditions. It is also a requirement for carbohydrates which serve as precursors either directly or indirectly for synthesis of glycogen in liver and muscle. Muscle cannot function efficiently or at a high level of power output if reserves of glycogen are low or sub-optimal. Depletion of glycogen in athletes results in poor performance and poor efficiency. Use of specific carbohydrates as an ergogenic aid has been proved to increase or maintain the stores of glycogen and availability of blood glucose.

The food products of this invention may comprise chewable or edible bars, sweets, cookies, biscuits, lozenges or chewing gum. Chewable or edible bars are preferred.

According to the present invention a high energy multi-saccharide food product comprises a saccharide component including 3 to 37% w/w galactose, 0 to 25% w/w of creatine and optional further ingredients selected from carbohydrate; fibre and fat.

Amounts and percentages in this specification are by weight unless indicated otherwise and are selected to total 100%.

The amount of galactose is preferably 5 to 20%, more preferably 5 to 15%.

The saccharide component also includes glucose. In a first preferred embodiment equal amounts of glucose and galactose are provided. In a second preferred embodiment the amount of galactose is greater than the amount of glucose.

Use of galactose affords several advantages. It is not insulogenic, that is it does not itself induce an insulin response, hence its use is associated with less of an insulin response than the equivalent mass of glucose. Products in accordance with this invention may be used by diabetics or persons who ae intolerant to lactose. Galactose can be used

rapidly by the liver for synthesis of glycogen or glucose. It is less likely to cause dental erosion than other sugars.

Use of creatine is optional. Preferred embodiments of the invention incorporate 10 to 25% creatine. The use of creatine is preferably such that the conversion to creatinine is inhibited. This conversion is a natural equilibrium. Creatinine is rapidly excreted by the kidneys. In order to minimise or prevent conversion to creatinine it is preferred that the creatine is encapsulated as granules or powder in a dry water-impervious shell. Microencapsulation is preferred. In this way the creatine is released in the stomach by dissolution. Alternatively the creatine may be isolated from the moist part of an edible bar by formulation in layers alternatively or in addition to encapsulation. For example the creatine may be contained in a separate layer of the food bar or lozenge.

Food products in accordance with this invention are useful in general cases of creatine depletion, for example in vegetarians or individuals where build-up of muscle function is needed or is clinically advisable.

Exercise makes excessive demands on substrates both within and external to muscle. Creatine phosphate is derived from both dietary creatine and from endogenous synthesis. Creatine phosphate is essential for short term energy supply during anaerobic conditions and also for energy transfer from mitochondria to contractile muscle. Muscle cannot function efficiently or at a high level of power output if reserves of creatine are low or sub-optimal. Depletion of creatine in athletes causes poor performance and poor efficiency.

Galactose may be provided as a pure ingredient which is mixed with glucose, starch and other ingredients during manufacture. Alternatively a glucose-galactose syrup such as may be prepared by hydrolysis of lactose may be employed. The amount of galactose in such a syrup may be supplemented by additional pure galactose.

Use of fibre in the bar is advantageous because different fibre products influence the release of sugars, affect the binding of various components and advantageously delay digestion. An amount of 0 to 5% may be employed. Furthermore the galactose or galactose-glucose syrup may be absorbed onto the fibre prior to manufacture. In this way the absorption of galactose may be retarded.

In an alternative embodiment the food products may have an external coating containing galactose in order to facilitate rapid absorption of galactose.

Formulations having a higher concentration of galactose are preferred in order to enhance galactose up-take by the liver and rapid production of glycogen. Increased amounts of galactose decrease the amount of lipid manufactured from glucose. Galactose is not a direct fat precursor. This is advantageous as lipids do not afford a rapid energy source.

The invention is further described by means of example but not in any limitative sense.

The following Tables and Examples list the ingredients of compositions of food products in accordance with this invention. These products may be manufactured into bars, sweets or lozenges using conventional methods.

In a layered arrangement the creatine powder or aggregate may be covered with a hard dry sugar layer. Alternatively or in addition a chocolate containing layer may be used as a moisture barrier. The creatine containing layer may be provided as a laminar cylindrical layer disposed within the bar as the inner layer. In this way the creatine containing component may be encapsulated. Alternatively or in addition ingredients such as fibre, nuts and dried fruit may be layered onto the creatine to form a laminate. The fibre layer may incorporate syrup to form a composite layer.

The outermost layer of the bar or other food product may comprise a single thin layer of hard sugar for example composed of galactose or a mixture of galactose with glucose or sucrose. Such an arrangement of the sugar layer dissolves rapidly when portions of the bar pass into the stomach.

In alternative food products the creatine powder or aggregate may be covered with a hard sugar mixture, chocolate or both to form particles with a mass of 100 to 500 mg. These can be combined with the remaining ingredients to form dispersed units within the matrix, for example as chocolate chips within a cookie. Such an encapsulated arrangement may incorporate layers as previously described.

The following tables contain general ranges of preferred ingredients.

TABLE 1

Ingredient	Range (% w/w)	Comments
Carbohydrate	50-75	Mono, di, oligosaccharides, syrup etc.
Fat	0-10	Saturated and unsaturated
Fibre	0-10	
Creatine	0-25	As monohydrate
Protein	0-15	·
Vitamins	50-100% of RDA	Full range
Galactose	5-20	
Dried Fruit	0-15	
Seeds and Nuts	0-15	
Glucose	0-10	
Flavours	As necessary	
Stabilisers	1-3	
Water	0-30	

TABLE 2

	Example	Example	Example	Example	Example	Example
	1	2	3	4	5	6
Cornstarch	20g	10g	20g	10g	10g	8g
Maltodextrin	20g	10g	20g	10g	10g	8g
Raw cane sugar	2g	2g	2g	2g	2g	2g
Fructose	3g	3g	3g	3g	3g	
Refined cane sugar	5g	5g	5g	5g	5g	
Glucose	5g	5g			5g	5g
Galactose	5g	5g			5g	5g
Glucose/Galactose			10g	10g		
syrup						
Fat	10g	10g	10g	10g	10g	5g
Fibre	5g	5g	5g	5g	5g	5g
Creatine	_	20g		20g		20g
Vitamins	lg	lg	lg	1g	lg	lg
Protein	10g	10g	10g	10g	10g	7g
Flavours	lg	lg	lg	lg	1g	1g
Stabilisers	2g	2g	2g	2g	2g	2g
Water	llg	llg	llg	llg	llg	11g
Fruit					10g	10g
Seeds and Nuts					10g	10g

	Example	Example	Example	Example	Example	Example
	7	8	9	10	11	12
Cornstarch	20g	10g	20g	10g	10g	8g
Maltodextrin	20g	10g	20g	10g	10g	8g
Raw cane sugar	2g	2g	2g	2g	2g	2g
Fructose	3g	3g	3g	3g	3g	
Refined cane sugar	5g	5g	5g	5g	5g	
Glucose	5g	5g			5g	5g
Galactose	5g	5g			5g	5g
Glucose/Galactose			10g	10g		
Fat	10g	10g	10g	10g	10g	5g
Fibre	5g	5g	5g	5g	5g	5g
Creatine	_	20g		20g		20g
Vitamins	lg	lg	lg	lg	lg	lg
Protein	10g	10g	10g	10g	10g	7g
Flavours	1g	lg	lg	lg	1g	lg
Stabilisers	2g	2g	2g	2g	2g	2g
Water	5g	5g	5g	5g	5g	5g
Fruit	3g	3g	3g	3g	13g	13g
Seeds and Nuts	3g	3g	3g	3g	13g	13g

	Example	Example	Example	Example	Example	Example
	13	14	15	16	17	18
Cornstarch	15g	5g	15g	5g	5g	8g
Maltodextrin	15g	5g	15g	5g	5g	8g
Raw cane sugar	2g	2g	2g	2g	2g	2g
Fructose	3g	3g	3g	3g	3g	
Refined cane	5g	5g	5g	5g	5g	
sugar						
Glucose	5g	5g			5g	5g
Galactose	5g	5g			5g	5g
Glucose/Galactose			10g	10g		
syrup						
Fat	10g	10g	10g	10g	18g	3g
Fibre	5g	5g	5g	5g	2g	2g
Creatine		20g		20g		20g
Vitamins	1g	lg	1g	1g	1g	1g
Protein	5g	5g	5g	5g	5g	2g
Flavours	lg	lg	1g	1g	1g	lg
Stabilisers	2g	2g	2g	2g	2g	2g
Water	20g	20g	20g	20g	20g	20g
Fruit	3g	3g	3g	3g	13g	13g
Seeds and Nuts	3g	3g	3g	3g	8g	8g

CLAIMS

WO 01/28360

fibre

1. An energy multi-saccharide food product including: a saccharide component including 3 to 37% w/w galactose; 0 to 25% w/w creatine; and

optional further ingredients selected from: carbohydrate, fibre and fat.

2. A food product as claimed in claim 1 comprising:

galactose 5 to 20% creatine 0 to 25% carbohydrate 50 to 75% fat 0 to 10%

and optional further ingredients, wherein the ingredients total 100%.

0 to 10%

- 3. A food product as claimed in claim 1 or 2, wherein the amount of galactose is 5 to 20%, preferably 5 to 15%.
- 4. A food product as claimed in any preceding claim, wherein the saccharide component includes glucose.
- 5. A food product as claimed in claim 4 including equal amounts of galactose and glucose.
- 6. A food product as claimed in claim 3, wherein the amount of galactose is greater than the amount of glucose.
- 7. A food product as claimed in any preceding claim, wherein the amount of creatine is 10 to 25%.

- 8. A food product as claimed in any preceding claim, wherein the creatine is encapsulated as granules or powder.
- 9. A food product as claimed in claim 8, wherein the creatine is microencapsulated.
- 10. A food product as claimed in any preceding claim, wherein the creatine is contained in a separate layer.
- 11. A food product as claimed in any preceding claim, having an outermost layer of hard sugar comprising galactose or a mixture of galactose and sucrose.

INTERNATIONAL SEARCH REPORT

Ional Application No PCT/GB 00/03995

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A23L1/09 A23L1/29

A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, FSTA

C DOCUMENTS (CONSIDERED	TO BE RELEVANT
		TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
χ	US 5 780 094 A (KING RODERICK FREDERICK GERARD) 14 July 1998 (1998-07-14)	1-6
Y	column 1, line 49 -column 1, line 56 column 2, line 1 -column 2, line 11 column 2, line 34 -column 2, line 37; claims 1-3,7; examples 1,2,7,8	7-11
X	EP 0 340 491 A (BIODYN AG) 8 November 1989 (1989-11-08) claims 1-3; examples 9,10	1,4,6
Υ	WO 96 18313 A (UNIV NOTTINGHAM ;GREENHAFF PAUL LEONARD (GB); GREEN ALLISON LESLEY) 20 June 1996 (1996-06-20) claims 2,6-10,14,15,17-19; example 1	7-11

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 	 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
21 February 2001 Name and mailing address of the ISA European Patent Office, P.B. 5618 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo ni,	06/03/2001 Authorized officer
Fax: (+31-70) 340-3016	Vernier, F

INTERNATIONAL SEARCH REPORT

Inte Ional Application No
PCT/GB 00/03995

:(Continua alegory °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	 In the state of the No.
alegory °	Citation of document, with indication, where appropriate, of the relevant passages	
		Relevant to claim No.
1	US 5 726 146 A (BYRD EDWARD A ET AL) 10 March 1998 (1998-03-10) column 2, line 66 -column 3, line 11; claims 1,2,11,16,19; table 1	1-11
4	PEYREBRUNE M C ET AL: "The effects of oral creatine supplementation on performance in single and repeated sprint swimming." JOURNAL OF SPORTS SCIENCES, vol. 16, no. 3, April 1998 (1998-04), pages 271-279, XP000974232 ISSN: 0264-0414 page 272, column 2, paragraph 3 -page 273, column 2, paragraph 1	1-11
•	:	•

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte .ional Application No
PCT/GB 00/03995

Patent document cited in search repor	t	Publication date	Patent family member(s)	Publication date
US 5780094	A	14-07-1998	AT 158690 T AU 686338 B AU 1816295 A CA 2183336 A CN 1140397 A DE 69500806 D DE 69500806 T DK 744902 T EP 0744902 A ES 2110317 T WO 9522260 A GR 3025777 T	15-10-1997 05-02-1998 04-09-1995 24-08-1995 15-01-1997 06-11-1997 09-04-1998 11-05-1998 04-12-1996 01-02-1998 24-08-1995 31-03-1998
EP 0340491	 А	08-11-1989	JP 3059485 B JP 9508804 T DE 3815513 A DE 3815794 A EP 0349712 A JP 1309668 A JP 1320968 A	04-07-2000 09-09-1997
WO 9618313	А	20-06-1996	AT 194462 T AU 4185696 A CA 2208047 A DE 69518008 D EP 0798971 A ES 2150020 T PT 798971 T US 5968900 A	15-07-2000 03-07-1996 20-06-1996 17-08-2000 08-10-1997 16-11-2000 29-12-2000 19-10-1999
US 5726146	Α	10-03-1998	NONE	